• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

142.58 -7.38 (-4.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Palvella Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands ↗
August 16, 2026
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN... 
Via MarketBeat
News headline image
Palvella (PVLA) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy. 
Via The Motley Fool
Topics Earnings
News headline image
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 05, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗
May 07, 2026
Via Chartmill
News headline image
Palvella Therapeutics Q2 Earnings Call Highlights ↗
August 04, 2026
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call ↗
August 04, 2026
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
News headline image
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
June 30, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
June 29, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗
June 27, 2026
Focused on rare skin disease therapies, this clinical-stage biotech just reported a notable insider sale amid a year of sharp stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 03, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 02, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 27, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
May 21, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
May 20, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Q1 Earnings Call Highlights ↗
May 08, 2026
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting... 
Via MarketBeat
Topics Earnings
News headline image
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 07, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 04, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 20, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
April 13, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 07, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
March 31, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
March 30, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 27, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap